Acute graft-versus-host disease after liver transplantation

Role of withdrawal of immunosuppression in therapeutic management

Srinath Chinnakotla, Douglas M. Smith, Rana Domiati-Saad, Edward D. Agura, David L. Watkins, George Netto, Tadahiro Uemura, Edmund Q. Sanchez, Marlon F. Levy, Goran B. Klintmalm

Research output: Contribution to journalArticle

Abstract

Graft-versus-host disease (GVHD) after liver transplantation is rare but associated with a very high mortality (over 85%). Most treatments focus on increasing immunosuppression, addition of antibody preparations such as OKT3 and antithymocyte globulin to eliminate the donor lymphocytes, and supporting myelopoiesis by use of cytokines. However, the results are very poor. We reasoned that a better therapeutic approach would be to reduce the immunosuppression and allow the patient's immune system an opportunity to reject the allograft donor T cells. We tested this novel therapeutic approach in 3 patients diagnosed with GVHD. Two patients had rapid loss of donor T cell chimerism and resolution of their symptoms. The other patient continued to progress to severe GVHD and died. The patients who responded to withdrawal of immunosuppression had a later onset of symptoms and a lower level of donor CD3+ T cells at the start of treatment. We conclude that larger studies are needed to further evaluate these results and to determine what factors may affect the likelihood that a patient may respond to this approach.

Original languageEnglish (US)
Pages (from-to)157-161
Number of pages5
JournalLiver Transplantation
Volume13
Issue number1
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Graft vs Host Disease
Liver Transplantation
Immunosuppression
Tissue Donors
T-Lymphocytes
Therapeutics
Myelopoiesis
Muromonab-CD3
Chimerism
Antilymphocyte Serum
Allografts
Immune System
Lymphocytes
Cytokines
Mortality
Antibodies

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Chinnakotla, S., Smith, D. M., Domiati-Saad, R., Agura, E. D., Watkins, D. L., Netto, G., ... Klintmalm, G. B. (2007). Acute graft-versus-host disease after liver transplantation: Role of withdrawal of immunosuppression in therapeutic management. Liver Transplantation, 13(1), 157-161. https://doi.org/10.1002/lt.20982

Acute graft-versus-host disease after liver transplantation : Role of withdrawal of immunosuppression in therapeutic management. / Chinnakotla, Srinath; Smith, Douglas M.; Domiati-Saad, Rana; Agura, Edward D.; Watkins, David L.; Netto, George; Uemura, Tadahiro; Sanchez, Edmund Q.; Levy, Marlon F.; Klintmalm, Goran B.

In: Liver Transplantation, Vol. 13, No. 1, 2007, p. 157-161.

Research output: Contribution to journalArticle

Chinnakotla, S, Smith, DM, Domiati-Saad, R, Agura, ED, Watkins, DL, Netto, G, Uemura, T, Sanchez, EQ, Levy, MF & Klintmalm, GB 2007, 'Acute graft-versus-host disease after liver transplantation: Role of withdrawal of immunosuppression in therapeutic management', Liver Transplantation, vol. 13, no. 1, pp. 157-161. https://doi.org/10.1002/lt.20982
Chinnakotla, Srinath ; Smith, Douglas M. ; Domiati-Saad, Rana ; Agura, Edward D. ; Watkins, David L. ; Netto, George ; Uemura, Tadahiro ; Sanchez, Edmund Q. ; Levy, Marlon F. ; Klintmalm, Goran B. / Acute graft-versus-host disease after liver transplantation : Role of withdrawal of immunosuppression in therapeutic management. In: Liver Transplantation. 2007 ; Vol. 13, No. 1. pp. 157-161.
@article{f6e4c601a00f4cf69e4848cd8c54cd19,
title = "Acute graft-versus-host disease after liver transplantation: Role of withdrawal of immunosuppression in therapeutic management",
abstract = "Graft-versus-host disease (GVHD) after liver transplantation is rare but associated with a very high mortality (over 85{\%}). Most treatments focus on increasing immunosuppression, addition of antibody preparations such as OKT3 and antithymocyte globulin to eliminate the donor lymphocytes, and supporting myelopoiesis by use of cytokines. However, the results are very poor. We reasoned that a better therapeutic approach would be to reduce the immunosuppression and allow the patient's immune system an opportunity to reject the allograft donor T cells. We tested this novel therapeutic approach in 3 patients diagnosed with GVHD. Two patients had rapid loss of donor T cell chimerism and resolution of their symptoms. The other patient continued to progress to severe GVHD and died. The patients who responded to withdrawal of immunosuppression had a later onset of symptoms and a lower level of donor CD3+ T cells at the start of treatment. We conclude that larger studies are needed to further evaluate these results and to determine what factors may affect the likelihood that a patient may respond to this approach.",
author = "Srinath Chinnakotla and Smith, {Douglas M.} and Rana Domiati-Saad and Agura, {Edward D.} and Watkins, {David L.} and George Netto and Tadahiro Uemura and Sanchez, {Edmund Q.} and Levy, {Marlon F.} and Klintmalm, {Goran B.}",
year = "2007",
doi = "10.1002/lt.20982",
language = "English (US)",
volume = "13",
pages = "157--161",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Acute graft-versus-host disease after liver transplantation

T2 - Role of withdrawal of immunosuppression in therapeutic management

AU - Chinnakotla, Srinath

AU - Smith, Douglas M.

AU - Domiati-Saad, Rana

AU - Agura, Edward D.

AU - Watkins, David L.

AU - Netto, George

AU - Uemura, Tadahiro

AU - Sanchez, Edmund Q.

AU - Levy, Marlon F.

AU - Klintmalm, Goran B.

PY - 2007

Y1 - 2007

N2 - Graft-versus-host disease (GVHD) after liver transplantation is rare but associated with a very high mortality (over 85%). Most treatments focus on increasing immunosuppression, addition of antibody preparations such as OKT3 and antithymocyte globulin to eliminate the donor lymphocytes, and supporting myelopoiesis by use of cytokines. However, the results are very poor. We reasoned that a better therapeutic approach would be to reduce the immunosuppression and allow the patient's immune system an opportunity to reject the allograft donor T cells. We tested this novel therapeutic approach in 3 patients diagnosed with GVHD. Two patients had rapid loss of donor T cell chimerism and resolution of their symptoms. The other patient continued to progress to severe GVHD and died. The patients who responded to withdrawal of immunosuppression had a later onset of symptoms and a lower level of donor CD3+ T cells at the start of treatment. We conclude that larger studies are needed to further evaluate these results and to determine what factors may affect the likelihood that a patient may respond to this approach.

AB - Graft-versus-host disease (GVHD) after liver transplantation is rare but associated with a very high mortality (over 85%). Most treatments focus on increasing immunosuppression, addition of antibody preparations such as OKT3 and antithymocyte globulin to eliminate the donor lymphocytes, and supporting myelopoiesis by use of cytokines. However, the results are very poor. We reasoned that a better therapeutic approach would be to reduce the immunosuppression and allow the patient's immune system an opportunity to reject the allograft donor T cells. We tested this novel therapeutic approach in 3 patients diagnosed with GVHD. Two patients had rapid loss of donor T cell chimerism and resolution of their symptoms. The other patient continued to progress to severe GVHD and died. The patients who responded to withdrawal of immunosuppression had a later onset of symptoms and a lower level of donor CD3+ T cells at the start of treatment. We conclude that larger studies are needed to further evaluate these results and to determine what factors may affect the likelihood that a patient may respond to this approach.

UR - http://www.scopus.com/inward/record.url?scp=33846295188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846295188&partnerID=8YFLogxK

U2 - 10.1002/lt.20982

DO - 10.1002/lt.20982

M3 - Article

VL - 13

SP - 157

EP - 161

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 1

ER -